The Evolution of T-cell Dysfunction in AML – Tailored Antibody-based Immunotherapy toIncrease Response Rate and Overcome Innate and Adaptive Resistance

AML 中 T 细胞功能障碍的演变 â 定制基于抗体的免疫疗法，以提高反应率并克服先天性和适应性耐药性

• 批准号: 451580403
• 负责人: Professor Dr. Karl-Peter Hopfner
• 金额: --
• 依托单位: Genzentrum - Laboratorium für molekulare Biologie
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2020
• 资助国家: 德国
• 起止时间: 2019-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/451580403?language=en
• 关键词: Evolution; cell; Dysfunction; AML; Tailored

Treatment of AML by allogeneic stem cell transplantation is mediated by T cells but is hampered by a high mortality rate. We find that T-cell function is modulated through progressively evolving changes in phenotype and function of AML. Our goal is to unravel changes in T-cell responses and develop multi-specific anti¬body derivatives (msADs), tailored to interfere with immune checkpoint molecules in specific geno- and phenotype of AML subtypes.

通过异基因干细胞移植治疗AML由T细胞介导，但受到高死亡率的阻碍。我们发现，T细胞功能是通过AML的表型和功能的逐步演变的变化来调节的。我们的目标是揭示T细胞反应的变化并开发多特异性抗体衍生物（msAD），专门用于干扰AML亚型特定基因和表型中的免疫检查点分子。